December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

8.955 +0.075 (+0.84%)
Streaming Delayed Price Updated: 3:54 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Four Developments in Cancer Research That Occurred in 2022
Via Investor Brand Network
Topics Death
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Strategic Board Appointment of Faith L. Charles, JD
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial
Via Investor Brand Network
Machine Learning Effort Enables Large-Scale Cancer Study to Improve Boundary Detection
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Updates of Recent Key Events and Plans for Calendar 2023; Announces Public Offering to Raise Funding for Operations
Via Investor Brand Network
Four Facts You Need to Know About Brain Cancer
Via Investor Brand Network
New Study Finds Localized Cooling of Brain Tumors Slows Growth in Mice Models
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment
Via Investor Brand Network
Data Shows Increase in Mortality Among Patients with Malignant Brain Tumors
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial
Via Investor Brand Network
Research Recommends Reduction of Pediatric Brain Irradiation During Cancer Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in ‘Ask the CEO’ Event
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Friday
  On Friday, 72 companies hit new 52-week lows. 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Pricing for Public Offering
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
Why Shares Of Chinese Companies Are Trading Higher? Here Are 45 Stocks Moving In Tuesday's Mid-Day Session
Gainers Otonomy, Inc. (NASDAQ: OTIC) shares surged 74.2% to $0.1866. Otonomy recently posted a Q3 loss of $0.18 per share. 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place
Via Investor Brand Network
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time for another dive into the biggest pre-market stock movers with the shares rising and falling on Tuesday! 
Via InvestorPlace
Why Elbit Systems Shares Are Trading Lower By Over 10%; Here Are 24 Stocks Moving Premarket
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares rose 26.3% to $0.7994 in pre-market trading after the company received FDA 510K premarket clearance for PainShield Plus, its dual-actuator ultrasound... 
Via Benzinga
European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial
Via Investor Brand Network
Implanted Pump Holds Promise in Treating Brain Cancer
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations
Via Investor Brand Network
Researchers Turn to AI for Insights on Treating Brain Tumors
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2022 Financial Numbers, Corporate Update
Via Investor Brand Network
Scientists Look for Ways to Disable Sugar Molecule That Fuels Cancer Persistence
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin
Via Investor Brand Network
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.